These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27029727)

  • 61. Relevance of total PSA and free PSA prescriptions.
    Lamy PJ; Brouillet JP; Bermont L; Fouillet G; Loric S
    Ann Biol Clin (Paris); 2018 Dec; 76(6):659-663. PubMed ID: 30543191
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer.
    Munteanu VC; Munteanu RA; Onaciu A; Berindan-Neagoe I; Petrut B; Coman I
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32102477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Early detection of prostate cancer: is serum PSA testing alone sufficient?].
    Börgermann C; Vom Dorp F; Breuer G; Kliner S; Rübben H
    Urologe A; 2010 Nov; 49(11):1351-5. PubMed ID: 20959954
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prostate cancer: screening and early detection.
    Cookson MM
    Cancer Control; 2001; 8(2):133-40. PubMed ID: 11326167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review.
    Pecoraro V; Roli L; Plebani M; Trenti T
    Clin Chem Lab Med; 2016 Jul; 54(7):1123-32. PubMed ID: 26609863
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advances in the diagnostic options for prostate cancer.
    French WW; Wallen EM
    Postgrad Med; 2020 Dec; 132(sup4):52-62. PubMed ID: 32900250
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Narayan VM; Konety BR; Warlick C
    Int J Urol; 2017 May; 24(5):352-360. PubMed ID: 28345187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Circulating biomarkers for prostate cancer.
    Steuber T; Helo P; Lilja H
    World J Urol; 2007 Apr; 25(2):111-9. PubMed ID: 17345087
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prostate cancer screening: guidelines review and laboratory issues.
    Filella X; Albaladejo MD; Allué JA; Castaño MA; Morell-Garcia D; Ruiz MÀ; Santamaría M; Torrejón MJ; Giménez N
    Clin Chem Lab Med; 2019 Sep; 57(10):1474-1487. PubMed ID: 31120856
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [PROSTATE CANCER EARLY DETECTION USING PSA - CURRENT TRENDS AND RECENT UPDATES].
    Lavi A; Cohen M
    Harefuah; 2017 Mar; 156(3):185-188. PubMed ID: 28551942
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiparametric MRI in the PSA screening era.
    George AK; Pinto PA; Rais-Bahrami S
    Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [PSA-screening: sensible or meaningless?].
    Dubben HH
    Urologe A; 2009 Sep; 48(9):1103; author reply 1103-4. PubMed ID: 19727645
    [No Abstract]   [Full Text] [Related]  

  • 74. Genetic correction of PSA values using sequence variants associated with PSA levels.
    Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
    Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PSA testing beneficial for prostate cancer.
    Bagcchi S
    Lancet Oncol; 2014 Sep; 15(10):e424. PubMed ID: 25328952
    [No Abstract]   [Full Text] [Related]  

  • 76. [Prostate cancer - diagnostics and screening].
    Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Isoforms of free prostate-specific antigen].
    Haese A; Noldus J; Steuber T; Huland H; Lilja H
    Urologe A; 2004 Jun; 43(6):675-9. PubMed ID: 15221148
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Personalized prostate cancer screening: improving PSA tests with genomic information.
    Witte JS
    Sci Transl Med; 2010 Dec; 2(62):62ps55. PubMed ID: 21160075
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Epigenetic markers of early diagnostics of prostate cancer.].
    Peshkov MN
    Klin Lab Diagn; 2018; 63(10):605-609. PubMed ID: 30768880
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current early diagnostic biomarkers of prostate cancer.
    Qu M; Ren SC; Sun YH
    Asian J Androl; 2014; 16(4):549-54. PubMed ID: 24830695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.